A Case of Advanced Lung Squamous Cell Carcinoma with CLIP1-ALK Fusion Gene.
10.3779/j.issn.1009-3419.2022.102.29
- Author:
Yue YUAN
1
,
2
;
Zheng WANG
2
,
3
;
Xin NIE
1
,
2
;
Ping ZHANG
1
,
2
;
Lin LI
1
,
2
Author Information
1. Department of Oncology, Beijing Hospital
2. National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing 100730, China.
3. Department of Pathology, Beijing Hospital
- Publication Type:Journal Article
- Keywords:
ALK fusion gene;
ALK inhibitor;
Lung neoplasms
- MeSH:
Adenocarcinoma of Lung;
Anaplastic Lymphoma Kinase/genetics*;
Carcinoma, Non-Small-Cell Lung/pathology*;
Carcinoma, Squamous Cell/genetics*;
Humans;
Lung/pathology*;
Lung Neoplasms/pathology*;
Microtubule-Associated Proteins/genetics*;
Oncogene Proteins, Fusion/genetics*;
Protein Kinase Inhibitors/pharmacology*;
Receptor Protein-Tyrosine Kinases/genetics*
- From:
Chinese Journal of Lung Cancer
2022;25(9):696-700
- CountryChina
- Language:Chinese
-
Abstract:
Anaplastic lymphoma kinase (ALK) fusion gene is an important tumor driver gene of non-small cell lung cancer, accounting for about 5% of patients with non-small cell lung cancer, of which 97% are patients with lung adenocarcinoma. Since the first discovery of echinoderm microtubule associated protein-like 4 (EML4)-ALK fusion in patients with lung adenocarcinoma in 2007, a variety of ALK fusion partners have been detected. CLIP1-ALK fusion gene was detected by next generation sequencing (NGS) in this patient with advanced lung squamous cell carcinoma, and Alectinib and Ensartinib were taken orally on May 5, 2021. Aletinib was effective for this patient but the patients died on September 30, 2021. This is a report of lung squamous cell carcinoma patients with CLIP1-ALK fusion gene treated with ALK inhibitors.
.
